Prognostic Factors for Patients Undergoing Autologous Stem Cell Transplant for DLBCL
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
All articles by Jonathan Goodman, MPhil
Acalabrutinib With Obinutuzumab May Be Safe, Effective in Chronic Lymphocytic Leukemia
Patients who were treatment-naive had an overall response rate of 95%, while patients with relapsed/refractory disease had an overall response rate of 92%.
Therapeutic Drug Monitoring of Asparaginase in Acute Lymphoblastic Leukemia
Researchers assessed whether adjusted asparaginase dosage helps reduce toxicity while maintaining sufficient asparaginase depletion in children with ALL.
Treosulfan May Offer a New Standard for Prehematopoietic Stem Cell Transplantation Conditioning
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.
Measurable Residual Disease Status: A Strong Prognostic Indicator in B-Cell Acute Lymphoblastic Leukemia
Researchers conducted a meta-analysis of 23 studies to determine the influence of measurable residual disease on survival outcomes.
Racial Disparities Affect Myeloma Treatment, Though Survival May Be Similar
Time to initiation of therapy was significantly longer for black and Hispanic patients compared with white patients.
Single Nucleotide Polymorphisms Associated With ALL in Children With Down Syndrome
Researchers conducted a meta-analysis to evaluate possible associations between certain genetic variants and risk for acute lymphoblastic leukemia.
Factors Associated With Low Bone Mineral Density in Blood Cancer Survivors
Older age at diagnosis, white race, and body mass index below the fifth percentile were associated with low bone mineral density.
Next post in Hematologic Cancers
